Skip to main content
Scope Fluidics S.A. logo

Scope Fluidics S.A. — Investor Relations & Filings

Ticker · SCP ISIN · PLSCPFL00018 LEI · 259400EUNFX4E2BEHU15 WAR Professional, scientific and technical activities
Open in API
Filings indexed 518 across all filing types
Latest filing 2020-07-22 Capital/Financing Update
Country PL Poland
Listing WAR SCP

About Scope Fluidics S.A.

https://scopefluidics.com/

Scope Fluidics S.A. is a biotechnology company that develops innovative medical diagnostic solutions based on microfluidic technologies. The company's business model involves incubating projects within special-purpose vehicles (SPVs) with the goal of selling them to global strategic partners. Its primary project, developed by its subsidiary Bacteromic Sp. z o.o., is the BACTEROMIC system. This automated system provides rapid, comprehensive antimicrobial susceptibility testing (AST) to address the challenge of antibiotic resistance. Previously, the company developed the PCR|ONE system for rapid molecular diagnostics through its Curiosity Diagnostics SPV, which was acquired by Bio-Rad in 2022. The company focuses on creating fast, effective, and accessible diagnostic tools to improve healthcare outcomes.

Recent filings

Filing Released Lang Actions
Decyzja w sprawie struktury finansowania zwiększenia intensywności działań w projekcie PCR|ONE wchodzących w skład Programu Early Access – przekazanie opóźnionej informacji poufnej - Content (PL)
Capital/Financing Update Classification · 98% confidence The document discusses the Management Board's proposal to the Supervisory Board (Rada Nadzorcza) to seek authorization from the General Meeting (Walne Zgromadzenie) to increase the share capital within a target capital limit (kapitał docelowy) through the issuance of new shares, potentially excluding pre-emptive rights. This action is explicitly linked to financing the 'PCR|ONE' project and follows discussions with a European financial institution. The core subject is the proposed structure change related to capital raising and share issuance authorization. This directly aligns with the definition of 'Capital/Financing Update' (CAP). Although it mentions seeking authorization from the General Meeting, the primary focus is the capital structure change mechanism itself, not the voting results (DVA) or the meeting agenda (AGM-R). It is a detailed announcement regarding financing plans, not just a brief notice of a report (RPA/RNS).
2020-07-22 Polish
Decyzja o zwiększeniu intensywności działań w projekcie PCR|ONE wchodzących w skład Programu Early Access oraz o podjęciu działań zmierzających do pozyskania finansowania na ten cel – przekazanie o...
Regulatory Filings Classification · 95% confidence The document is written in Polish and discusses strategic business decisions by the Management Board ("Zarząd") regarding the expansion of the Early Access Program for the PCR|ONE system, driven by the COVID-19 pandemic and interest from potential buyers of the subsidiary Curiosity Diagnostics. It details operational plans (producing analyzers and cartridges), market analysis, and crucially, the need to secure additional financing of approximately 9 million EUR, potentially through new share issues. The text explicitly mentions delaying the disclosure of this information based on Article 17(1) and (4) of the EU Market Abuse Regulation (MAR) (Rozporządzenie Parlamentu Europejskiego i Rady (UE) Nr 596/2014). This type of announcement, detailing significant strategic operational changes and financing needs, often falls under regulatory disclosure requirements related to inside information. Since it is a detailed report on management strategy, operational changes, and financing plans, it is best classified as a general regulatory announcement or a report detailing management actions. Given the content focuses heavily on management decisions, strategic outlook, and financing needs, it aligns closely with the scope of a comprehensive regulatory filing that isn't a standard financial report (10-K, IR) or a specific management discussion (MDA). However, the core of the document is the management's detailed explanation of business trends, strategy adjustments (expanding the Early Access Program), and the resulting financing need. This strongly suggests 'Management Reports' (MDA) or a general 'Regulatory Filing' (RNS). Since it is a detailed report on management's assessment and plans, MDA is a strong candidate, but the explicit reference to MAR disclosure delay points towards a mandatory regulatory disclosure. Given the options, and that it is a detailed report on management's strategic response and financing plans, MDA (Management's detailed explanation of financial results, business trends, and outlook) is appropriate, although RNS (General regulatory announcements) is also plausible as a catch-all for MAR disclosures. I will lean towards MDA as the content is primarily strategic management commentary rather than just a brief regulatory notice.
2020-07-22 Polish
Aktualizacja informacji dotyczących aktualnego etapu rozwoju systemu PCR|ONE i systemu BacterOMIC - Content (PL)
Management Reports Classification · 98% confidence The document is a formal update from the Management Board ('Zarząd') of Scope Fluidics S.A. regarding the progress and delays in two key projects (PCR|ONE and BacterOMIC), referencing previous current reports ('raport bieżący'). It discusses timelines for clinical effectiveness testing, pre-registration tests, and certification, attributing delays to COVID-19 related hospital restrictions. This content—management providing detailed explanations of business trends, operational challenges, and outlook for specific projects—fits the definition of Management Reports (MDA), which typically includes detailed operational commentary beyond a simple earnings release (ER) or a formal financial statement (IR/10-K). It is not a general regulatory filing (RNS) or a report publication announcement (RPA) because it contains substantive operational updates, not just a notice that a report is available.
2020-07-10 Polish
Brak porozumienia z Agencją Badań Medycznych w kwestii istotnych postanowień umowy o dofinansowanie w ramach konkursu Covid-19 - Content (PL)
Legal Proceedings Report Classification · 99% confidence The document text discusses the failure to reach an agreement with the Medical Research Agency (ABM) regarding a significant funding agreement related to Covid-19, leading to the decision by Curiosity Diagnostics to withdraw from signing the agreement. The core subject is a dispute or failure in a major contractual/funding negotiation that impacts intellectual property rights and business processes. This situation constitutes a significant legal or regulatory matter affecting the company's operations and future, fitting best under 'Legal Proceedings Report' (LTR) as it details a breakdown in a major official/regulatory contract negotiation that has significant business implications, or potentially 'Regulatory Filings' (RNS) if it were a general announcement. Given the detailed description of the contractual dispute and its impact on IP rights, LTR is a strong candidate, although it is not a lawsuit, but a failed regulatory contract. Since it details a significant adverse event related to a regulatory body (ABM) and its contractual terms, and it is not a standard financial report, dividend notice, or management change, it is classified as a significant legal/contractual update. Given the options, LTR (Legal Proceedings Report) is the most appropriate fit for reporting on a major contractual dispute with a government agency that impacts core IP, even if it hasn't escalated to a formal lawsuit yet. If LTR is strictly for lawsuits, RNS (Regulatory Filings) would be the fallback, but LTR often covers significant regulatory/contractual disputes.
2020-06-26 Polish
Otrzymanie pozytywnej rekomendacji dot. wydania certyfikatu zgodności z normą ISO 13485:2016 dla Curiosity Diagnostics - Content (PL)
Audit Report / Information Classification · 95% confidence The document is a brief announcement (1207 characters) from the Management Board (Zarząd) of Scope Fluidics S.A. It reports the successful completion of a certification audit (ISO 13485:2016) by PCBC for a subsidiary, Curiosity Diagnostics. This event is explicitly linked to achieving a specific milestone in the company's development schedule, which was previously disclosed. Since this is a specific update regarding quality management system certification and regulatory compliance achievement, it fits best under 'Audit Report / Information' (AR) as it details the results of an audit, even though it's a positive recommendation rather than a final certificate issuance. It is not a full Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it pertains directly to an audit outcome. Q3 2020
2020-06-19 Polish
Informacja o warunkowej decyzji o przyznaniu przez Państwowy Urząd Własności Intelektualnej Chińskiej Republiki Ludowej patentu na wynalazek stanowiący kluczową technologię dla działania systemu PC...
Regulatory Filings Classification · 95% confidence The document is a short announcement (1239 characters) from a Polish company (Zarząd Scope Fluidics) informing about a conditional patent grant in China for a key technology component (PCR|ONE analyzer module). It details the significance of the patent and mentions previous grants in the US and Europe, referencing prior current reports ('raport bieżący'). Since this is a specific, material event announcement that doesn't fit the definitions for ER, IR, 10-K, or specific corporate actions like dividends or director dealings, and it is not merely announcing the publication of a larger report (RPA), it falls best under the general category for miscellaneous regulatory/material event disclosures, which is Regulatory Filings (RNS).
2020-06-09 Polish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.